American News Group News Commentary - The race to bring artificial intelligence into drug discovery has become one of the most closely watched stories in both biotech and technology. Pharmaceutical ...
The acquisition builds on an existing partnership and will allow Tempus to advance its cancer monitoring solutions.
Subseasonal forecasting, or the ability to predict weather trends two weeks to two months in advance, is a capability highly ...
Caris Life Sciences proprietary WES/WTS/WGS technology and massive data advantage underpin its leadership in oncology ...
Preview this article 1 min Personalis shareholders will receive $16.25 per share. The deal is expected to close in late 2026 ...
MarketBeat on MSN
Tempus AI bets on MRD testing growth with Personalis acquisition
Key Points Interested in Tempus AI, Inc.? Here are five stocks we like better. Tempus AI plans to acquire Personalis to ...
The AI in pathology market is witnessing strong growth, driven by the increasing adoption of digital pathology, rising cancer incidence, and the growing demand for faster and more accurate diagnostic ...
View post: Wells Fargo doubles down on AMD stock after Anthropic deal ...
Tempus AI Inc. (NASDAQ:TEM) is one of the top 10 hidden AI stocks to buy. On May 31, Tempus AI launched the next generation of Lens, an agentic AI platform designed to accelerate oncology drug ...
According to BCC Research, AI is helping medical plastics companies reduce production costs, improve product consistency and accelerate innovation for medical devices and healthcare ...
Nvidia was the first poster child of the AI revolution. OpenAI turned ChatGPT into a global phenomenon. Google, Microsoft, and Anthropic have since dominated headlines with ever-more-powerful models.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results